Opioid Policy InstituteApr 17, 2023

Interested in folks thoughts about our new op-ed with Mishka Terplan in @STAT

I have been chewing on the march-in rights for the opioid crisis since Jul 2020. This space has had so much profiteering and other ugly pharma behavior that has gone under the radar. There is a book worth of stuff.

So thankful I had the opportunity to work with Mishka and STAT to bring this from rattling around my head to print.

https://www.statnews.com/2023/04/17/otc-narcan-naloxone-price-availability/

OTC naloxone is a baby step toward making the life-saving medication accessible

The new over-the-counter status for naloxone is a no-brainer. But as people who work to fight the opioid epidemic, we fear that many others may be overstating the victory here.

STAT
Show threadOpioid Policy Institute

@STAT
Let's dial back our expectations of OTC naloxone (they are not grounded in reality) and start leaning into solutions (admittedly, big swings but insulin pricing debate has shown us sometimes we need sticks or the threat of sticks, not just carrots) that will impact access for people who need naloxone most.

We need to do more to get medicines into the bodies of people who need it. The federal gov't needs to help make that happen. OTC naloxone won't.

Apr 17, 2023 at 2:08pmWeb